Article

Abnormalities in visually guided saccades suggest corticofugal dysregulation in never-treated schizophrenia.

Center for Cognitive Medicine, University of Illinois at Chicago, Chicago, Illinois 60612, USA.
Biological Psychiatry (Impact Factor: 9.47). 02/2005; 57(2):145-54. DOI: 10.1016/j.biopsych.2004.10.024
Source: PubMed

ABSTRACT Previous studies have reported intact visually guided saccades in schizophrenia, but these are limited by potential acute and long-term pharmacological treatment effects, small sample sizes, and a failure to follow patients over time.
Visually guided saccades were examined in 44 antipsychotic-naive patients experiencing their first episode of schizophrenia prior to treatment and again after 6, 26, and 52 weeks of antipsychotic treatment. Thirty-nine matched healthy individuals were followed over the same period.
Before treatment, patients showed faster saccade latencies to unpredictable visual targets, suggesting reduced inhibitory regulation of brainstem saccade generators by neocortical attentional systems. Risperidone treatment reduced this deficit, suggesting a facilitation of attentional function, but haloperidol treatment did not. However, there was also a modest decline in saccade accuracy after risperidone treatment. The ability to sustain fixation of static central and peripheral targets was unimpaired before and after treatment.
These findings provide evidence for impairments in neocortical attentional systems that cause reduced corticofugal regulation of brainstem systems in schizophrenia. This dysfunction appears to be minimized by the atypical antipsychotic risperidone but at the cost of a subtle reduction in saccade accuracy, possibly mediated via adverse effects on cerebellar vermis function.

Full-text

Available from: John A Sweeney, Jan 02, 2014
0 Followers
 · 
137 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: There are hypotheses that traumatic brain injury (TBI) and schizophrenia might exhibit similar patterns of cognitive disorders in attention, executive function and memory. Yet, empirical studies comparing directly the two populations are extremely rare. The aim of this exploratory study was to compare performance of patients with TBI and schizophrenia in a task of selective attention. A group of TBI patients (n = 18), a group of patients with schizophrenia (n = 21), and a control group with no history of neurologic or psychiatric illness (n = 31) participated in this study. A paced paper-and-pencil cancellation task was completed by each participant, allowing for discrimination between intact and impaired attention subcomponents. Compared to the controls, both patient groups had (a) slower processing speed, (b) reduced target processing efficiency, (c) instant attentional overload, and (d) difficulties in discriminating targets from distractors. However, these deficits were of different degrees between the groups. Furthermore, (e) a marked selective impairment of processing of distractors was observed in patients with schizophrenia only, as well as (f) a failure to regulate attentional resources over time. Finally, (g) none of the groups showed any shifts in response strategies. These results suggest that there are large similarities in disturbances in selective attention between these two pathologies. Yet, whenever similar, these disturbances are of different degrees. Furthermore, there are some qualitative differences between the two pathologies.
    Psychologie Française 10/2014; DOI:10.1016/j.psfr.2014.08.002 · 0.30 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Individuals with autism spectrum disorder (ASD) show atypical scan paths during social interaction and when viewing faces, and recent evidence suggests that they also show abnormal saccadic eye movement dynamics and accuracy when viewing less complex and non-social stimuli. Eye movements are a uniquely promising target for studies of ASD as their spatial and temporal characteristics can be measured precisely and the brain circuits supporting them are well-defined. Control of saccade metrics is supported by discrete circuits within the cerebellum and brainstem - two brain regions implicated in magnetic resonance (MR) morphometry and histopathological studies of ASD. The functional integrity of these distinct brain systems can be examined by evaluating different parameters of visually-guided saccades.
    Molecular Autism 01/2014; 5(1):47. DOI:10.1186/2040-2392-5-47 · 5.49 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Neurocognitive deficits are associated with most psychotic disorders, but may differ across diagnosis and by treatment status. This ambiguity is partly addressed in longitudinal pre/post treatment studies with first episode patients. Antipsychotic-naïve first-episode schizophrenia patients have shown intact performance on a predictive saccade task that assesses simple motor learning, spatial abilities, and response planning. After antipsychotic treatment, however, schizophrenia patients performing this task show a selective impairment in the accuracy of anticipatory responses, generated from learned internal representations of the task stimulus. This finding is in line with other observations of antipsychotic medication effects on frontostriatal systems, particularly dorsolateral prefrontal cortex. We sought to replicate this provocative finding with an independent sample of antipsychotic-naïve first-episode schizophrenia patients and extend it by including a group of patients with first episode bipolar disorder with psychosis (BDP). Matched healthy controls were also studied in parallel. Schizophrenia patients demonstrated intact performance pretreatment followed by impairment post-treatment for accuracy of anticipatory responses, and worse accuracy was associated with higher antipsychotic dose. BDP patients displayed saccade accuracy deficits before and after treatment and had no correlation of performance and antipsychotic dose. The findings suggest different neural alterations early in the course of each psychotic disorder, and different vulnerabilities to antipsychotic treatment effects between schizophrenia and BDP.
    Schizophrenia Research 08/2014; 159(1). DOI:10.1016/j.schres.2014.07.028 · 4.43 Impact Factor